GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (FRA:87E) » Definitions » Deferred Tax

Dianthus Therapeutics (FRA:87E) Deferred Tax : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Dianthus Therapeutics's change in deferred tax for the three months ended in Mar. 2025 was €0.00 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.


Dianthus Therapeutics Deferred Tax Historical Data

The historical data trend for Dianthus Therapeutics's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Deferred Tax Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Deferred Tax
- - - -

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Deferred Tax Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Dianthus Therapeutics Deferred Tax Calculation

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dianthus Therapeutics Deferred Tax Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Dianthus Therapeutics Headlines

No Headlines